CSI Market
Sign In | Register

Cytomx Therapeutics Inc (CTMX) Annual Cash Flow Statement

Annual · GAAP · USD millions
Access CTMX quarterly Cash Flow →
Reviewing cash flow data across recent quarters allows users to assess how Cytomx Therapeutics Inc adapts its cash strategy across cycles.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Annual Report, GAAP in USD millions
ITEM 		(Dec 31 2025)
12 Months 		(Dec 31 2024) (Dec 31 2023) (Dec 31 2022) (Dec 31 2021)
Operating Activities
Income-17.37
Depreciation & amortization0.00
Amortization of Other Assets0.15
Increase (Decrease) in Deferred Revenue0.00
Restructuring & Impairment Charges0.00
Provision For Loan Losses Expensed0.00
Inventories Decrease /-Increase0.00
R & D, Environmental and Other Expense0.00
Gain (Loss) on Sale of Assets and Asset Impairment Charges0.40
Share-based Compensation6.30
Income (Loss) from Equity Method Investments0.00
Financial Instruments and Foreign Currency Transaction0.00
Increase Decrease In Accrued Liabilities And Other Liabilities Noncurrent-
Increase Decrease In Accrued Liabilities Income Tax Payable And Other Liabilities Noncurrent-
Noncash Lease Expense4.48
Increase Decrease In Accrued And Other Liabilities Noncurrent-3.05
Depreciation And Amortization Excluding Amortization Of Intangible Assets1.23
Income taxes0.00
Losses/ -gains on Investments net0.00
Increase (Decrease) in Accounts Receivable1.09
Increase (Decrease) in Accounts Payable0.22
Increase (Decrease) in Accrued Liabilities0.00
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense and Other Assets-1.24
Other Working Capital0.00
Other Noncash Income (Expense)0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities-67.80
Discontinued operations0.00
Net Cash flow from Operating Activities-75.59
Investing Activities
Capital Expenditures-0.22
Sale of Capital Items0.00
Short-term Investments Proceeds-59.52
Payments to Acquire Available-for-sale Securities, Debt0.00
Real Estate Investments0.00
Increase in Restricted Cash0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments to Acquire Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Acquisition Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities-59.74
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock110.45
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net-39.08
Proceeds From Stockholder Notes-
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations39.08
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities110.45
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow-75.81
Total Cash Flow-24.89
4 historic quarters locked

Sign in to unlock the full Cytomx Therapeutics Inc cash flow history.

Sign In Create Free Account

About Cytomx Therapeutics Inc Annual Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-K filings and normalized by CSIMarket.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001193125-26-107146

Figures are derived from filed reports and may be restated. Historical data is subject to revision.

Untitled Document 





                    


    



  Get the full CSIMarket dataset:
  Subscribe
  API
  License